← Human Trials & Peer-Reviewed Studies
Semaglutide and Neovascular Age-Related Macular Degeneration among Adults with Type 2 Diabetes: An Observational Health Data Sciences and Informatics Network Study
Plain-language guide to PMID 42229813 (2026): observational study of Semaglutide.
Key Facts
- PMID
- 42229813
- Journal
- Ophthalmology
- Year
- 2026
- Study type
- Observational Study
- Authors
- Cai CX et al. (47 authors)
- DOI
- 10.1016/j.ophtha.2026.05.034
What This Study Did, in Plain Language
What Was Tested
This observational study looks at Semaglutide.
To investigate the potential association of semaglutide use and neovascular age-related macular degeneration (NVAMD).
Why It Was Studied
Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
Who Took Part
By PubMed's age tags, the people studied were middle-aged adults and older adults, both men and women.
Adults with type 2 diabetes (T2D) taking semaglutide, other glucagon-like peptide-1 receptor agonists (GLP-1RAs; e.g., dulaglutide or exenatide), or non-GLP-1RAs (e.g., empagliflozin, sitagliptin, or glipizide).
How the Study Was Run
Retrospective study across 12 databases in the Observational Health Data Sciences and Informatics network from December 1, 2017, through December 31, 2024.
The association between semaglutide use and NVAMD was assessed using 2 approaches: an active-comparator cohort design and a self-controlled case series analysis.
The latter used conditional Poisson regression models to estimate incidence rate ratios (IRRs).
A random-effects meta-analysis was used to generate network-wide HR and IRR estimates.
What Was Measured
Topics PubMed links to this paper include Semaglutide, Diabetes Mellitus, Type 2, Glucagon-Like Peptides, Hypoglycemic Agents, Wet Macular Degeneration, Incidence and Immunoglobulin Fc Fragments.
The authors tagged it with the keywords Big data, Neovascular age-related macular degeneration and Observational Health Data Sciences and Informatics.
What This Means in Plain Language
This is an observational study of Semaglutide.
The abstract goes on to report its results in about 5 sentences; this page does not restate them, so read the paper for the findings and their limits.
The publication is from 2026 (Ophthalmology), a journal based in United States.
More context: the Semaglutide compound page, all human trials.
Our Notes on the Compound
Semaglutide: The active ingredient in several prescription GLP-1 receptor agonist medicines (Ozempic, Wegovy, oral tablets).
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.